Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.719308
Keywords
severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019; liver disturbance; drugs; treatment
Categories
Ask authors/readers for more resources
The outbreak of SARS-CoV-2 in Wuhan at the end of 2019 led to the naming of the infectious disease as COVID-19 by the World Health Organization. Research indicates that SARS-CoV-2 patients may experience liver disturbances, but the impact of COVID-19 treatment drugs on liver function remains controversial. Evaluating the potential liver damage caused by various drugs is crucial for guiding clinical practice.
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, at the end of 2019. The World Health Organization named the resulting infectious disease as coronavirus disease-2019 (COVID-19). Many studies concluded that patients infected with SARS-CoV-2 have different degrees of liver disturbance. However, the relationship between the drugs used for COVID-19 treatment and liver disturbance remains controversial. It is essential to evaluate the potential liver damage caused by various drugs in order to help guide clinical practice. This review analyzed the effect of drugs on hepatic function during the treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available